StockData
Innoviva, Inc. logo

Innoviva, Inc. (INVA) stock

INVANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3039% below fair value
$18.30−0.19 (-1.03%)

Close on Nov 17, 2026Market cap $1.32BP/E 9.3Yield –

Innoviva operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Innoviva's operating cash flow for the twelve months ending Sep 30, 2026 was $183.47M, down 9.0% year over year. For fiscal 2025 it was $196.93M, up 4.4% from the year before. Over ten years it grew 34.5% a year on average. The highest annual figure on record is $363.81M in fiscal 2021.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$196.93M+4.4%
FY2024Dec 31, 2024$188.69M+33.8%
FY2023Dec 31, 2023$141.06M-30.1%
FY2022Dec 31, 2022$201.73M-44.6%
FY2021Dec 31, 2021$363.81M+16.2%
FY2020Dec 31, 2020$313.11M+21.6%
FY2019Dec 31, 2019$257.46M+15.2%
FY2018Dec 31, 2018$223.53M+57.7%
FY2017Dec 31, 2017$141.75M+132.4%
FY2016Dec 31, 2016$60.98M+502.0%
FY2015Dec 31, 2015$10.13M–
FY2014Dec 31, 2014-$130.72M–
FY2013Dec 31, 2013-$129.60M–
FY2012Dec 31, 2012-$127.51M–
FY2011Dec 31, 2011-$88.34M–
FY2010Dec 31, 2010-$75.14M–
FY2009Dec 31, 2009-$58.06M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$41.70M-16.1%
Q2 FY2026Jun 30, 2026$51.97M+17.9%
Q1 FY2026Mar 31, 2026$35.28M-27.4%
Q4 FY2025Dec 31, 2025$54.51M-8.0%
Q3 FY2025Sep 30, 2025$49.73M+2.1%
Q2 FY2025Jun 30, 2025$44.07M+0.8%
Q1 FY2025Mar 31, 2025$48.62M+31.2%
Q4 FY2024Dec 31, 2024$59.24M+78.1%
Q3 FY2024Sep 30, 2024$48.69M+10.8%
Q2 FY2024Jun 30, 2024$43.72M+14.5%
Q1 FY2024Mar 31, 2024$37.05M+44.2%
Q4 FY2023Dec 31, 2023$33.26M+273.7%
Q3 FY2023Sep 30, 2023$43.94M+180.1%
Q2 FY2023Jun 30, 2023$38.18M-51.7%
Q1 FY2023Mar 31, 2023$25.68M-73.8%
Q4 FY2022Dec 31, 2022$8.90M-91.0%
Q3 FY2022Sep 30, 2022$15.69M-83.8%
Q2 FY2022Jun 30, 2022$79.04M-6.6%
Q1 FY2022Mar 31, 2022$98.10M+16.6%
Q4 FY2021Dec 31, 2021$98.38M+15.4%
Q3 FY2021Sep 30, 2021$96.71M+29.7%
Q2 FY2021Jun 30, 2021$84.61M+6.0%
Q1 FY2021Mar 31, 2021$84.11M+14.5%
Q4 FY2020Dec 31, 2020$85.28M+27.5%
Q3 FY2020Sep 30, 2020$74.56M+29.9%
Q2 FY2020Jun 30, 2020$79.79M+41.2%
Q1 FY2020Mar 31, 2020$73.48M-4.1%
Q4 FY2019Dec 31, 2019$66.91M+8.3%
Q3 FY2019Sep 30, 2019$57.40M-4.5%
Q2 FY2019Jun 30, 2019$56.50M+9.2%
Q1 FY2019Mar 31, 2019$76.66M+53.6%
Q4 FY2018Dec 31, 2018$61.78M+29.1%
Q3 FY2018Sep 30, 2018$60.12M+38.2%
Q2 FY2018Jun 30, 2018$51.73M+128.5%
Q1 FY2018Mar 31, 2018$49.91M+79.8%
Q4 FY2017Dec 31, 2017$47.86M+127.0%
Q3 FY2017Sep 30, 2017$43.49M–
Q2 FY2017Jun 30, 2017$22.64M–
Q1 FY2017Mar 31, 2017$27.76M–
Q4 FY2016Dec 31, 2016$21.09M–

More Innoviva figures

See a number that looks wrong?